Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01265511 · ClinicalTrials.gov registry record · Phase 2
Study of SCY-635, Pegasys and Copegus in Hepatitis C
A Phase 2 study, sponsored by Scynexis.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01265511: Completed Phase 2 study, sponsored by Scynexis.
NCT01265511 is a Phase 2 study that has completed, run by Scynexis. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01265511, a Phase 2 study, has completed, sponsored by Scynexis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study will examine the effectiveness of 28 days of triple combination therapy including SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An additional 20 weeks of treatment with the currently approved standard of care will be offered to all participants. The Week 24 visit will be the last on-study visit. After the Week 24 visit, all subjects with undetectable HCV RNA will be given the option to continue treatment with standard of care for an additional 24 weeks (out to Week 48) under the care of their Principal Investigator.
Interventions
- DRUG Placebo
- DRUG Copegus
- DRUG Pegasys
- DRUG SCY-635
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-11 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
What the finished NCT01265511 record still lists
NCT01265511 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01265511 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01265511 about?
NCT01265511 is a clinical study titled "Study of SCY-635, Pegasys and Copegus in Hepatitis C". This study will examine the effectiveness of 28 days of triple combination therapy including SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An additional 20 weeks of treatment with the currently approved standard of care will be offered to all participants. The We...
What is the current status of trial NCT01265511?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-11. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01265511?
The interventions under investigation include: Placebo (DRUG), Copegus (DRUG), Pegasys (DRUG), SCY-635 (DRUG).
Who is sponsoring clinical trial NCT01265511?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01265511's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia